Riskpilot← Back to searchSign inGet full accessXri Med AB
ABActiveOrg 5592316037Akvarievägen 54Medical specialists activities · NACE 8622Est. 20192 employees
Revenue 2025
SEK 466K
-57% vs 2024
EBITDA margin
-45.3%
-162% vs 2024
Equity ratio
47.6%
Financial strength
Net profit 2025
SEK -49K
-120% vs 2024
| Revenue | SEK 466K | -57% |
| EBITDA | SEK -211K | -162% |
| Net profit | SEK -49K | -120% |
| Total assets | SEK 525K | -46% |
| Equity | SEK 250K | -50% |
| Employees | 2 | — |
Legal name
Xri Med AB
Org number
5592316037
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
12 december 2019
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva medicinsk hälso- och sjukvård inom specialist allmänmedicin och legitimerad sjuksköterska samt uthyrning av sjukvårdspersonal och och därmed förenlig verksamhet. Vidare bedriva handel med värdepapper och fastigheter och därmed förenlig verksamhet.
Address
Akvarievägen 54
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 571 | 582 | 1 870 | 1 087 | 466 |
| Staff expenses | — | −425 | −795 | −604 | −581 |
| EBITDA | 231 | 76 | 923 | 340 | −211 |
| Depreciation & amort. | −0 | — | — | −29 | −32 |
| EBIT | 231 | 76 | 923 | 311 | −243 |
| Net financials | — | — | 0 | −0 | −6 |
| Profit before tax | 231 | 76 | 723 | 311 | −49 |
| Tax | −50 | −16 | −151 | −65 | — |
| Net profit | 181 | 60 | 572 | 245 | −49 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 290 | 247 | 1 585 | 968 | 525 |
| Equity | 231 | 141 | 653 | 499 | 250 |
| Long-term debt | 8 | 0 | — | 62 | 52 |
| Short-term debt | 51 | 106 | 732 | 207 | 223 |
| Total debt | 59 | 106 | 732 | 269 | 275 |
EBITDA margin
-45.3%
This company
15.8%
Market median
-387% vs market
20212025
Equity ratio
47.6%
This company
38.2%
Market median
+25% vs market
20212025
Return on equity
-19.6%
This company
18.4%
Market median
-207% vs market
20212025
Net profit margin
-10.5%
This company
8.1%
Market median
-230% vs market
20212025
Asset turnover
0.89×
This company
1.12×
Market median
+21% vs market
20212025
Debt / equity
1.10×
This company
0.62×
Market median
-77% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2019-12-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SK Authorized Recipient of Service | Authorized Recipient of Service | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Xri Med AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sofia Kalamboki | Authorized Recipient of Service | 0 companies |
| Anthoula Bokotsou | Deputy Board Member | 0 companies |
| Christos Skriapas | Board of Directors | 0 companies |